The $17.9m contract from National Institutes of Health (NIH) aims to develop and enhance efficacy of MVA-BN-based human vaccine against the viral hemorrhagic fever Marburg.
The other $1m US Department of Homeland Security (DHS) Science and Technology Directorate contract will support the development of a MVA-BN-based animal vaccine against Foot-and-mouth disease.
Bavarian Nordic president and CEO Anders Hedegaard said the new contracts depict the uniqueness of MVA-BN platform for infectious disease vaccines and cancer immunotherapeutics.
"The MVA-BN platform has broad applicability, an excellent safety profile and established manufacturing capacity, making it one of the most attractive vaccine technologies to meet the U.S. government’s preparedness needs, as well as demonstrating commercial value," Hedegaard added.
MVA-BN is a vaccine platform that addresses variety of infectious diseases, including biological threats.
The new contracts are expected to further enhance the existing partnership between Bavarian Nordic and the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases.